Human recombinant growth hormone

Phase 2Biologic

UUniversity of Maryland, Baltimore

Human recombinant growth hormone is one of 33 biologic programs targeting Osteoporosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteoporosisActive, not recruiting

Human Papilloma VirusRecruiting

OsteoporosisPreclinical

Active, not recruiting

Human Papilloma VirusPhase 2

Recruiting

Competition

Competitive Landscape

37 competitors in Osteoporosis

#DrugCompanyPhaseTrials

Forteo

AAlmaject

Approved

39 2

Zometa

Pfizer

Approved

16 3

Fosamax

OOrganon and Co

Approved

32 4

Evista

Eli Lilly

Approved

7 5

Rocaltrol

Jazz Pharmaceuticals

Approved

3 6

Sensipar

Calciferol

Estrace

Achromycin V

WWyeth-Lederle Vaccines

Approved

1 10

Andriol

AAuxilium

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Human Papilloma Virus

NCT06624839

Clinical

Trials by Indication[1]

Cystic Fibrosis1 trial

Growth Hormone Use in Cystic Fibrosis - a Multicenter Study

Completed·NNational Center for Research Resources (NCRR)·Phase 3·NCT00005112

Heart Failure1 trial

Evaluation of the Effect of Human Recombinant Growth Hormone in Patients With Advanced Heart Failure

Completed·HHamilton Health Sciences Corporation·Phase 2·NCT00182169·80 enrolled

Osteoporosis1 trial

Growth Hormone for Osteoporosis Pseudoglioma Syndrome

Withdrawn·UUniversity of Maryland, Baltimore·N/A·NCT01614171

Human Papilloma Virus1 trial

A PRe-pOsT Interventional Study Evaluating Gardasil Nine-valent Human Papilloma Virus (HPV) Vaccine Humoral and Cellular Immune Responses in People With or Without HIV

Recruiting·UUniversity of Maryland, Baltimore·Phase 2·NCT06624839·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Human recombinant growth hormone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Human recombinant growth hormone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Human recombinant growth hormone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Maryland, Baltimore company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Maryland, Baltimore

Human recombinant growth hormone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Cystic Fibrosis1 trial

Heart Failure1 trial

Osteoporosis1 trial

Human Papilloma Virus1 trial

References

Drug Info

Quick Facts

Related News